Quotient (QTNTQ) 10-Q 13 Nov 14 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2014	Nov. 12, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'QTNT	'
Entity Registrant Name	'Quotient Ltd	'
Entity Central Index Key	'0001596946	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	14,376,547

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$17,110	$7,192
Trade accounts receivable, net	2,650	2,439
Inventories	4,424	4,557
Prepaid expenses and other current assets	4,843	5,200
Total current assets	29,027	19,388
Property and equipment, net	17,736	8,556
Intangible assets, net	1,079	967
Other non-current assets	611	897
Total assets	48,453	29,808
Current liabilities:	'	'
Accounts payable	5,004	5,343
Accrued compensation and benefits	1,768	2,014
Accrued expenses and other current liabilities	5,955	4,453
Financial liability in respect of share warrants	7,545	421
Current portion of long-term debt	1,500	'
Current portion of lease incentive	442	485
Current portion of capital lease obligation	281	183
Total current liabilities	22,495	12,899
Long-term debt, less current portion	13,692	15,105
Lease incentive, less current portion	1,989	2,423
Capital lease obligation, less current portion	373	154
Total liabilities	38,549	30,581
Commitments and contingencies	'	'
Shareholders' equity (deficit)	'	'
Distribution in excess of capital	-15,863	-16,793
Accumulated other comprehensive income (loss)	-1,440	305
Accumulated deficit	-29,630	-15,295
Total shareholders' equity (deficit)	9,904	-31,536
Total liabilities, redeemable convertible preference shares and shareholders' equity	48,453	29,808
A Preference Shares [Member]	'	'
Current liabilities:	'	'
Preferred stock value	'	13,180
B Preference Shares [Member]	'	'
Current liabilities:	'	'
Preferred stock value	'	14,991
C Preference Shares [Member]	'	'
Current liabilities:	'	'
Preferred stock value	'	2,592
A Ordinary Shares [Member]	'	'
Shareholders' equity (deficit)	'	'
Common stock value	'	'
B Ordinary Shares [Member]	'	'
Shareholders' equity (deficit)	'	'
Common stock value	'	'
Ordinary Shares [Member]	'	'
Shareholders' equity (deficit)	'	'
Common stock value	56,837	247
Total shareholders' equity (deficit)	$56,837	$247

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Preferred stock, shares issued	0	28,232,528
Preferred stock, shares outstanding	0	28,232,528
Common stock, par value	'	'
Common stock, shares issued	14,376,547	342,142
Common stock, shares outstanding	14,376,547	342,142
A Preference Shares [Member]	'	'
Preferred stock, par value	'	'
Preferred stock, shares issued	0	12,719,954
Preferred stock, shares outstanding	0	12,719,954
B Preference Shares [Member]	'	'
Preferred stock, par value	'	'
Preferred stock, shares issued	0	14,583,407
Preferred stock, shares outstanding	0	14,583,407
C Preference Shares [Member]	'	'
Preferred stock, par value	'	'
Preferred stock, shares issued	0	929,167
Preferred stock, shares outstanding	0	929,167
A Ordinary Shares [Member]	'	'
Common stock, par value	'	'
Common stock, shares issued	0	244,141
Common stock, shares outstanding	0	244,141
B Ordinary Shares [Member]	'	'
Common stock, par value	'	'
Common stock, shares issued	0	37,957
Common stock, shares outstanding	0	37,957
Ordinary Shares [Member]	'	'
Common stock, par value	'	'
Common stock, shares issued	14,376,547	60,044
Common stock, shares outstanding	14,376,547	60,044

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Product sales	$4,527	$4,515	$9,794	$8,422
Other revenues	'	'	650	2,768
Total revenue	4,527	4,515	10,444	11,190
Cost of revenue	-2,706	-2,275	-5,157	-4,330
Gross profit	1,821	2,240	5,287	6,860
Operating expenses:	'	'	'	'
Sales and marketing	-609	-610	-1,306	-1,230
Research and development, net of government grants	-5,435	-1,591	-9,120	-3,209
General and administrative expense:	'	'	'	'
Compensation expense in respect of share options and management equity incentives	-283	-223	-509	-422
Other general and administrative expenses	-3,715	-1,807	-6,979	-3,487
Total general and administrative expense	-3,998	-2,030	-7,488	-3,909
Total operating expense	-10,042	-4,231	-17,914	-8,348
Operating loss	-8,221	-1,991	-12,627	-1,488
Other expense	'	'	'	'
Interest expense, net	-538	-81	-1,072	-158
Other, net	-2,960	-7	-636	-39
Other expense, net	-3,498	-88	-1,708	-197
Loss before income taxes	-11,719	-2,079	-14,335	-1,685
Provision for income taxes	0	0	0	0
Net loss	-11,719	-2,079	-14,335	-1,685
Other comprehensive income (loss):	'	'	'	'
Change in fair value of effective portion of foreign currency cash flow hedges	-159	'	-253	'
Foreign currency gain (loss)	-1,865	332	-1,492	479
Other comprehensive income (loss)	-2,024	332	-1,745	479
Comprehensive loss	-13,743	-1,747	-16,080	-1,206
Net loss available to ordinary shareholders - basic and diluted	($11,719)	($2,079)	($14,335)	($1,685)
Loss per share - basic and diluted	($0.82)	($7.20)	($1.06)	($6.41)
Weighted-average shares outstanding - basic and diluted	14,376,547	288,661	13,584,197	263,088

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND CHANGES IN SHAREHOLDERS' DEFICIT (USD $)	Total	Redeemable Convertible Preference Shares [Member]	Ordinary Shares [Member]	Distribution in Excess of Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning balance at Mar. 31, 2014	($31,536)	$30,763	$247	($16,793)	$305	($15,295)
Beginning balance, Shares at Mar. 31, 2014	'	28,232,528	342,142	'	'	'
Conversion of shares, Amount	31,287	-30,763	30,866	421	'	'
Conversion of shares, Shares	'	-28,232,528	9,034,405	'	'	'
Issue of shares, net of expenses, Amount	25,724	'	25,724	'	'	'
Issue of shares, net of expenses, Shares	'	'	5,000,000	'	'	'
Net loss	-14,335	'	'	'	'	-14,335
Change in the fair value of the effective portion of foreign currency cash flow hedges	-253	'	'	'	-253	'
Foreign currency translation gain (loss)	-1,492	'	'	'	-1,492	'
Other comprehensive income (loss)	-1,745	'	'	'	-1,745	'
Stock-based compensation	509	'	'	509	'	'
Ending balance at Sep. 30, 2014	$9,904	'	$56,837	($15,863)	($1,440)	($29,630)
Ending balance, Shares at Sep. 30, 2014	'	'	14,376,547	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
OPERATING ACTIVITIES:	'	'
Net loss	($14,335)	($1,685)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	599	240
Share-based compensation	509	422
Amortization of lease incentive	-235	'
Amortization of deferred debt issue costs	393	'
Change in fair value of financial liability in respect of share warrants	-984	'
Net change in assets and liabilities:	'	'
Trade accounts receivable, net	-372	-498
Inventories	-35	-505
Accounts payable and accrued liabilities	1,496	-71
Accrued compensation and benefits	-162	-342
Other assets	58	-267
Net cash used in operating activities	-13,068	-2,706
INVESTING ACTIVITIES:	'	'
Purchase of property and equipment	-10,058	-167
Purchase of intangible assets	-197	-7
Net cash used in investing activities	-10,255	-174
FINANCING ACTIVITIES:	'	'
Proceeds from (repayment of) finance leases	338	-99
Proceeds from issuance of ordinary and preference shares	34,254	150
Net cash generated from financing activities	34,592	51
Effect of exchange rate fluctuations on cash and cash equivalents	-1,351	150
Change in cash and cash equivalents	9,918	-2,679
Beginning cash and cash equivalents	7,192	4,219
Ending cash and cash equivalents	17,110	1,540
Supplemental cash flow disclosures:	'	'
Income taxes paid	0	0
Interest paid	$683	$240

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Description of Business and Basis of Presentation	'
	Note 1. Description of Business and Basis of Presentation
	Description of Business
	The principal activity of Quotient Limited (the “Company”) and its subsidiaries (the “Group”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide.
	Basis of Presentation
	The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and are unaudited. In accordance with those rules and regulations, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements.
	In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) considered necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. The March 31, 2014 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The financial statements should be read in conjunction with the audited consolidated financial statements at and for the year ended March 31, 2014 included in the Company’s Annual Report on Form 10-K for the year then ended. The results of operations for the quarter and the six months ended September 30, 2014 are not necessarily indicative of the results of operations that may be expected for the year ending March 31, 2015 and any future period.
	As of September 30, 2014, the Company had cash and cash equivalents of $17.1 million, including $0.3 million of cash held in a restricted account as part of the arrangements relating to the lease of the Company’s property in Eysins, Switzerland.
	The Company plans to continue investing in the development of MosaiQ™, including through increased expenditure on research and development associated with assay development, development of the MosaiQ™ instrument and converting and equipping the consumable manufacturing facility for MosaiQ™ in Eysins, Switzerland.  During the remainder of the current fiscal year, the Company anticipates gross expenditure of approximately $30 million associated with the ongoing development of MosaiQ™, although this amount may change materially. To maintain the current rate of development for MosaiQ™, the Company will therefore need to obtain additional funding, both for the remainder of the current fiscal year and for the period thereafter until the Company is cash flow positive following the commercial launch of MosaiQ™.  The Company intends to seek this additional funding from various potential financing sources, including from strategic partners or from the sale of new equity securities. The Company’s Directors are confident that additional funding can be secured and accordingly have prepared the condensed financial statements on the going concern basis. However, there can be no assurance that the Company will be able to obtain such additional funding on favorable terms or at all.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2. Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.
	Cash and cash equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2014 and March 31, 2014, all cash and cash equivalents comprised readily accessible cash balances except for $319 at September 30, 2014 and $345 at March 31, 2014 held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary.
	Trade accounts receivable
	Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms.
	Concentration of Credit Risks and Other Uncertainties
	The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting entirely of foreign exchange contracts, are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing.
	The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of September 30, 2014 and 99% at March 31, 2014. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of September 30, 2014 and March 31, 2014. This customer represented 37% and 53% of the accounts receivable balances as of September 30, 2014 and March 31, 2014, respectively.
	The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the six months ended September 30, 2014 and September 30, 2013. This customer represented 54% and 58% of total product sales for the six months ended September 30, 2014 and September 30, 2013, respectively.
	Fair Value of Financial Instruments
	The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs:
	–	Level 1—Quoted prices in active markets for identical assets or liabilities.
	–	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	–	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	See Note 6, “Commitment and Contingencies,” for information and related disclosures regarding the Company’s fair value measurements.
	Inventory
	Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of September 30, 2014 and March 31, 2014.
	Property and equipment
	Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows:
	–	Plant, machinery and equipment—4 to 25 years;
	–	Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset.
	Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred.
	Intangible Assets and Goodwill
	Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows:
	Customer relationships—5 years
	Brands associated with acquired cell lines—40 years
	Product licenses—10 years
	Other intangibles assets—7 years
	The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the six month periods ended September 30, 2014 or September 30, 2013.
	Revenue Recognition
	The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.
	The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved.
	In June 2013, the Company entered into an agreement with Ortho-Clinical Diagnostics Inc. (“OCD”) to develop a range of rare antisera products. The Company had been working on this project for more than a year before the formal agreement was signed with OCD. Under the terms of the agreement, the Company is entitled to receive milestone payments of $2,750 upon the receipt of CE-marks for the rare antisera products, $1,400 upon the receipt of FDA approval of the rare antisera products and two further milestones of $500 each upon the updating of the CE-mark and FDA approvals to cover use of the products on OCD’s automation platform. The Company concluded that as each of these milestones required significant levels of development work to be undertaken and there was no certainty at the start of the project that the development work would be successful, these milestones are substantive and will be accounted for under the milestone method of revenue recognition. The agreement also contains one further milestone of $650 payable upon fulfillment of $250 of cumulative orders of the rare antisera products covered by the agreement. This payment represents a royalty payment and was recognized in the six month period ended September 30, 2014 when the sales target was achieved. During the six month period ended September 30, 2013, the Company recognized $2,750 of milestone revenue relating to the achievement of the CE marketing milestone.
	Research and Development
	Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense.
	Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Condensed Consolidated Statements of Comprehensive Loss.
	In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures).

Intangible_Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	Note 3. Intangible Assets
		30-Sep-14
		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted Ave. Remaining Useful Life
	Customer relationships	$	3,192	$	(3,192	)	$	—		—
	Brands associated with acquired cell lines		658		(116	)		542	32.9 years
	Product licenses		763		(226	)		537	7.0 years
	Other intangibles		208		(208	)		—		—
	Total	$	4,821	$	(3,742	)	$	1,079
		31-Mar-14
		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted Ave. Remaining Useful Life
	Customer relationships	$	3,283	$	(3,283	)	$	—		—
	Brands associated with acquired cell lines		677		(112	)		565	33.4 years
	Product licenses		589		(200	)		389	6.6 years
	Other intangibles		213		(200	)		13	0.4 years
	Total	$	4,762	$	(3,795	)	$	967

Debt

Debt	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 4. Debt
	Long-term debt comprises:
		Sept 30,			March 31,
		2014			2014
	Total debt	$	15,000		$	15,000
	Less current portion		(1,500	)		—
	Long-term debt	$	13,500		$	15,000
	Fees due on final repayment of debt		487			487
	Fair value of associated share warrant, net of amortization		(295	)		(382	)
		$	13,692		$	15,105
	On December 9, 2013, the Company drew down $15,000 under a new secured credit facility agreement with MidCap Financial LLC. The new facility is repayable over a four year period with no repayments being due until 18 months from the date of drawdown and then equal amounts being repayable monthly over the remaining 30 months. The facility bears interest at LIBOR plus 6.7%. The LIBOR rate applicable is the higher of the actual market rate from time to time or 2.0%.
	At September 30, 2014, the outstanding debt is repayable as follows:
	Within 1 year	$	1,500
	Between 1 and 2 years		6,000
	Between 2 and 3 years		6,000
	Between 3 and 4 years		1,500
	Total debt	$	15,000

Consolidated_Balance_Sheet_Det

Consolidated Balance Sheet Detail	6 Months Ended
	Sep. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Consolidated Balance Sheet Detail	'
	Note 5. Consolidated Balance Sheet Detail
	Inventory
	The following table summarizes inventory by category for the dates presented:
		Sept 30,			March 31,
		2014			2014
	Raw materials	$	1,214		$	1,420
	Work in progress		2,353			2,031
	Finished goods		857			1,106
	Total inventories	$	4,424		$	4,557
	Property and equipment
	The following table summarizes property and equipment by categories for the dates presented:
		Sept 30,			March 31,
		2014			2014
	Plant and Machinery	$	15,109		$	7,063
	Leasehold improvements		5,199			3,594
	Total property and equipment		20,308			10,657
	Less: accumulated depreciation		(2,572	)		(2,101	)
	Total property and equipment, net	$	17,736		$	8,556
	Depreciation expenses were $557 and $188 in the six month periods ended September 30, 2014 and September 30, 2013 respectively.
	Accrued compensation and benefits
	Accrued compensation and benefits consist of the following:
		Sept 30,			March 31,
		2014			2014
	Salary and related benefits	$	151		$	75
	Accrued vacation		25			26
	Accrued payroll taxes		335			281
	Accrued incentive payments		1,257			1,632
	Total accrued compensation and benefits	$	1,768		$	2,014
	Accrued expenses and other current liabilities
	Accrued expenses and other current liabilities consist of the following:
		Sept 30,			March 31,
		2014			2014
	Accrued legal and professional fees	$	125		$	2,007
	Accrued interest		109			112
	Goods received not invoiced		582			590
	Accrued development expenditure		4,178			799
	Other accrued expenses		961			945
	Total accrued expenses and other current liabilities	$	5,955		$	4,453

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 6. Commitments and Contingencies
	Government Grant
	In 2008, the Company was awarded research and development grant funding from Scottish Enterprise amounting to £1,791, for the development of its Q Screen product. The total grant claimed to September 30, 2014 is £1,790. Regular meetings are held to update Scottish Enterprise with the status of the project and while the terms of the grant award provide for full repayment of the grant in certain circumstances, the Company does not consider that any repayment is likely.
	Hedging arrangements
	The Company’s subsidiary in the United Kingdom (“UK”) has entered into nine forward exchange contracts to sell $300 and purchase pounds sterling at a rate of £1:$1.7227 in each calendar month through June 2015 as a hedge of its U.S. dollar denominated revenues.
	Share warrants
	As part of its initial public offering in April the Company issued 5 million warrants each to acquire 0.8 of an ordinary share for a price of $8.80 per whole share.  The financial statements include a financial liability in respect of these warrants which is equal to the market price of the warrants at the end of each financial period.
	The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
		30-Sep-14
		Level 1			Level 2		Level 3		Total
	Assets:
	Foreign currency forward contracts	$	—		$	—	$	—	$	—
	Total assets measured at fair value	$	—		$	—	$	—	$	—
		30-Sep-14
		Level 1			Level 2		Level 3		Total
	Liabilities:
	Foreign currency forward contracts	$	159		$	—	$	—	$	159
	Fair value of share warrants		7,545			—		—		7,545
	Total liabilities measured at fair value	$	7,704		$	—	$	—	$	7,704
		31-Mar-14
		Level 1			Level 2		Level 3		Total
	Assets:
	Foreign currency forward contracts	$	94		$	—	$	—	$	94
	Total assets measured at fair value	$	94		$	—	$	—	$	94
		31-Mar-14
		Level 1			Level 2		Level 3		Total
	Liabilities:
	Fair value of share warrants	$	—		$	—	$	421	$	421
	Total liabilities measured at fair value	$	—		$	—	$	421	$	421
	The change in the estimated fair value of share warrant liabilities is summarized below:
	March 31,2014	$	421
	Exercise of warrants		—
	Transfer of liability to shareholders' equity upon the conversion of the preference share		(421	)
	warrant to a warrant in respect of ordinary shares
	Issue of ordinary share warrants as part of the company's initial public offering		8,529
	Change in fair value of ordinary share warrants		(984	)
	30-Sep-14	$	7,545

Ordinary_Deferred_and_Preferen

Ordinary, Deferred and Preference Shares	6 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Ordinary, Deferred and Preference Shares	'
	Note 7. Ordinary, Deferred and Preference Shares
	Ordinary and Deferred shares
	The Company’s issued and outstanding ordinary and deferred shares consist of the following:
		Shares Issued
		and Outstanding
		Sept 30,		March 31,		Par value
		2014		2014
	Ordinary shares		14,376,547		60,044	$	—
	A Ordinary shares		—		244,141		—
	B Ordinary shares		—		37,957		—
	Total		14,376,547		342,142	$	—
	Preference shares
	The Company’s issued and outstanding preference shares consist of the following:
		Shares Issued				Liquidation
		and Outstanding				amount per share
		Sept 30,		March 31,		Sept 30,		March 31,
		2014		2014		2014		2014
	A Preference shares		—		12,719,954	$	—	$	1.32
	B Preference shares		—		14,583,407	$	—	$	1.28
	C Preference shares		—		929,167	$	—	$	3.11
	Total		—		28,232,528
	On April 3, 2014, all of the outstanding A ordinary shares, B ordinary shares and preference shares were converted into ordinary shares. The ordinary shares then outstanding were consolidated on the basis of 32 new ordinary shares for every existing 100 ordinary shares. The number of ordinary and deferred shares and number of options and warrants to acquire ordinary shares are presented in these financial statements on the basis of the number after this consolidation. The numbers of preference shares are shown on the basis of the numbers before this consolidation.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	Note 8. Share-Based Compensation
	The Company records share-based compensation expense in respect of options and restricted stock units (“RSU’s”) issued under its share incentive plans and in respect of the deferred shares issued to employees. Share-based compensation expense amounted to $509 and $422 in the six month periods ended September 30, 2014 and September 30, 2013, respectively.
	Share option activity
	The following table summarizes share option activity:
			Number			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life (Months)		Aggregate
			of Share Options								Intrinsic
			Outstanding								Value (1)
	Outstanding — March 31, 2014			779,462		$	2.92		109		$	3,960
	Granted			556,500			8.07		120			—
	Exercised			—			—			—		—
	Forfeited			(15,480	)		—			—		—
	Outstanding — September 30, 2014			1,320,482		$	5.06		108		$	5,771
	Exercisable — September 30, 2014			206,112		$	1.94		101		$	1,544
	-1	Intrinsic value is calculated as the difference between the fair value of the Company’s ordinary shares as of the end of each reporting period and the exercise price of the option. The Company’s closing share price on September 30, 2014 was $9.43.
	The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any:
	Grant Date		Number of			Weighted Average Exercise Prices			Ordinary Shares		Intrinsic
			Options Granted						Fair Value Per		Value
									Share at Grant
									Date
	29-Apr-14			524,900		$	8		$	8	$	—
	6-Aug-14			31,600		$	9.26		$	9.26	$	—
	Determining the fair value of share incentive awards
	The fair value of each share incentive grant was determined by the Company using the Black-Scholes options pricing model.
	Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.
	Expected volatility. The expected volatility was based on the historical share volatilities of a number of the Company’s publicly listed peers over a period equal to the expected terms of the options as the Company did not have a sufficient trading history to use the volatility of its own ordinary shares.
	Fair value of ordinary shares. Transactions involving the preference share capital of the Company determined the fair values of the preference shares at those dates. The preference shares had preferred rights versus the ordinary shares as regards capital redemption and dividends but after all other shares had been paid out the balance of any residual assets was shared amongst the ordinary shareholders. The preference shareholders may have converted their shares to ordinary shares at any time.
	Based on these share rights, the fair value of the ordinary shares would not have exceeded the fair value of the preference shares but may have equalled it, if it appeared likely that the value of the Company as a whole exceeded the entitlements of the preference shares thus making it more likely than not that the preference shareholders would have opted to convert their shares.
	The directors have considered the progress of the Company at each option award date and determined the fair market value of the ordinary shares by reference to the fair values of the preference shares plus an appropriate discount.
	Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield in effect at the time of grant.
	Expected term. The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards.
	Expected dividend. According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price.
	A summary of the weighted-average assumptions applicable to the share options issued in the current financial year is as follows:
			29-Apr-14			6-Aug-14
	Risk-free interest rate			2.69	%		2.46	%
	Weighted average expected lives (years)			3			3
	Volatility			59.83	%		59.39	%
	Dividend yield			—			—
	Weighted average grant date fair value (per share)		$	8		$	9.26
	Number granted			524,900			31,600
	During the quarter ended September 30, 2014, the Company awarded 50,000 restricted stock units to a non-executive director upon his appointment as a director of the Company.  These vest in equal annual installments over the four year period following the date of grant.

Net_Loss_Per_Share

Net Loss Per Share	6 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Note 9. Net Loss Per Share
	In accordance with ASC 260 “Earnings Per Share”, basic earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus potential ordinary shares considered outstanding during the period, as long as the inclusion of such shares is not anti-dilutive. Potential ordinary shares consist of the incremental ordinary shares issuable upon the exercise of share options (using the treasury shares method), the conversion of the Company’s deferred and preference shares and the warrants to acquire preference shares.
	The following table sets forth the computation of basic and diluted earnings per ordinary share.
		Quarter ended						Six months ended
		30-Sep						30-Sep
		2014			2013			2014			2013
	Numerator:
	Net loss	$	(11,719	)	$	(2,079	)	$	(14,335	)	$	(1,685	)
	Net loss available to ordinary shareholders	$	(11,719	)	$	(2,079	)	$	(14,335	)	$	(1,685	)
	- basic and diluted
	Denominator:
	Weighted-average shares outstanding		14,376,547			288,661			13,584,197			263,088
	- basic and diluted
	Loss per share - basic and diluted	$	(0.82	)	$	(7.20	)	$	(1.06	)	$	(6.41	)
	The options to purchase ordinary shares, and prior to their conversion to ordinary shares, the deferred shares, the A preference shares, the B preference shares, the C preference shares and the warrants to purchase A preference shares, B preference shares and C preference shares were excluded from the above computations of earnings per share.
	B preference shares and C preference shares were participating securities with no contractual obligation to share in the losses of the Company. Accordingly, no losses were allocated to B preference shares and C preference shares in the calculation of loss per share in the periods presented.
	No cumulative A preference share dividend was included in the net loss for EPS calculation as A preference share dividends, based on their terms were not considered earned and they received no dividend at the time of their conversion to ordinary shares.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.
Cash and Cash Equivalents	'
	Cash and cash equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2014 and March 31, 2014, all cash and cash equivalents comprised readily accessible cash balances except for $319 at September 30, 2014 and $345 at March 31, 2014 held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary.
Trade Accounts Receivable	'
	Trade accounts receivable
	Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms.
Concentration of Credit Risks and Other Uncertainties	'
	Concentration of Credit Risks and Other Uncertainties
	The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting entirely of foreign exchange contracts, are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing.
	The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of September 30, 2014 and 99% at March 31, 2014. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of September 30, 2014 and March 31, 2014. This customer represented 37% and 53% of the accounts receivable balances as of September 30, 2014 and March 31, 2014, respectively.
	The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the six months ended September 30, 2014 and September 30, 2013. This customer represented 54% and 58% of total product sales for the six months ended September 30, 2014 and September 30, 2013, respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs:
	–	Level 1—Quoted prices in active markets for identical assets or liabilities.
	–	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	–	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	See Note 6, “Commitment and Contingencies,” for information and related disclosures regarding the Company’s fair value measurements.
Inventory	'
	Inventory
	Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of September 30, 2014 and March 31, 2014.
Property and Equipment	'
	Property and equipment
	Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows:
	–	Plant, machinery and equipment—4 to 25 years;
	–	Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset.
	Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred.
Intangible Assets and Goodwill	'
	Intangible Assets and Goodwill
	Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows:
	Customer relationships—5 years
	Brands associated with acquired cell lines—40 years
	Product licenses—10 years
	Other intangibles assets—7 years
	The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the six month periods ended September 30, 2014 or September 30, 2013.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.
	The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved.
	In June 2013, the Company entered into an agreement with Ortho-Clinical Diagnostics Inc. (“OCD”) to develop a range of rare antisera products. The Company had been working on this project for more than a year before the formal agreement was signed with OCD. Under the terms of the agreement, the Company is entitled to receive milestone payments of $2,750 upon the receipt of CE-marks for the rare antisera products, $1,400 upon the receipt of FDA approval of the rare antisera products and two further milestones of $500 each upon the updating of the CE-mark and FDA approvals to cover use of the products on OCD’s automation platform. The Company concluded that as each of these milestones required significant levels of development work to be undertaken and there was no certainty at the start of the project that the development work would be successful, these milestones are substantive and will be accounted for under the milestone method of revenue recognition. The agreement also contains one further milestone of $650 payable upon fulfillment of $250 of cumulative orders of the rare antisera products covered by the agreement. This payment represents a royalty payment and was recognized in the six month period ended September 30, 2014 when the sales target was achieved. During the six month period ended September 30, 2013, the Company recognized $2,750 of milestone revenue relating to the achievement of the CE marketing milestone.
Research and Development	'
	Research and Development
	Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense.
Stock-Based Compensation	'
	Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Condensed Consolidated Statements of Comprehensive Loss.
	In determining fair value of the stock-based compensation payments, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures).

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets	'
		30-Sep-14
		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted Ave. Remaining Useful Life
	Customer relationships	$	3,192	$	(3,192	)	$	—		—
	Brands associated with acquired cell lines		658		(116	)		542	32.9 years
	Product licenses		763		(226	)		537	7.0 years
	Other intangibles		208		(208	)		—		—
	Total	$	4,821	$	(3,742	)	$	1,079
		31-Mar-14
		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted Ave. Remaining Useful Life
	Customer relationships	$	3,283	$	(3,283	)	$	—		—
	Brands associated with acquired cell lines		677		(112	)		565	33.4 years
	Product licenses		589		(200	)		389	6.6 years
	Other intangibles		213		(200	)		13	0.4 years
	Total	$	4,762	$	(3,795	)	$	967

Debt_Tables

Debt (Tables)	6 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-Term Debt	'
	Long-term debt comprises:
		Sept 30,			March 31,
		2014			2014
	Total debt	$	15,000		$	15,000
	Less current portion		(1,500	)		—
	Long-term debt	$	13,500		$	15,000
	Fees due on final repayment of debt		487			487
	Fair value of associated share warrant, net of amortization		(295	)		(382	)
		$	13,692		$	15,105
Schedule of Outstanding Debt	'
	At September 30, 2014, the outstanding debt is repayable as follows:
	Within 1 year	$	1,500
	Between 1 and 2 years		6,000
	Between 2 and 3 years		6,000
	Between 3 and 4 years		1,500
	Total debt	$	15,000

Consolidated_Balance_Sheet_Det1

Consolidated Balance Sheet Detail (Tables)	6 Months Ended
	Sep. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Summary of Inventory	'
	The following table summarizes inventory by category for the dates presented:
		Sept 30,			March 31,
		2014			2014
	Raw materials	$	1,214		$	1,420
	Work in progress		2,353			2,031
	Finished goods		857			1,106
	Total inventories	$	4,424		$	4,557
Summary of Property and Equipment	'
	The following table summarizes property and equipment by categories for the dates presented:
		Sept 30,			March 31,
		2014			2014
	Plant and Machinery	$	15,109		$	7,063
	Leasehold improvements		5,199			3,594
	Total property and equipment		20,308			10,657
	Less: accumulated depreciation		(2,572	)		(2,101	)
	Total property and equipment, net	$	17,736		$	8,556
Summary of Accrued Compensation and Benefits	'
	Accrued compensation and benefits consist of the following:
		Sept 30,			March 31,
		2014			2014
	Salary and related benefits	$	151		$	75
	Accrued vacation		25			26
	Accrued payroll taxes		335			281
	Accrued incentive payments		1,257			1,632
	Total accrued compensation and benefits	$	1,768		$	2,014
Summary of Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities consist of the following:
		Sept 30,			March 31,
		2014			2014
	Accrued legal and professional fees	$	125		$	2,007
	Accrued interest		109			112
	Goods received not invoiced		582			590
	Accrued development expenditure		4,178			799
	Other accrued expenses		961			945
	Total accrued expenses and other current liabilities	$	5,955		$	4,453

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
		30-Sep-14
		Level 1			Level 2		Level 3		Total
	Assets:
	Foreign currency forward contracts	$	—		$	—	$	—	$	—
	Total assets measured at fair value	$	—		$	—	$	—	$	—
		30-Sep-14
		Level 1			Level 2		Level 3		Total
	Liabilities:
	Foreign currency forward contracts	$	159		$	—	$	—	$	159
	Fair value of share warrants		7,545			—		—		7,545
	Total liabilities measured at fair value	$	7,704		$	—	$	—	$	7,704
		31-Mar-14
		Level 1			Level 2		Level 3		Total
	Assets:
	Foreign currency forward contracts	$	94		$	—	$	—	$	94
	Total assets measured at fair value	$	94		$	—	$	—	$	94
		31-Mar-14
		Level 1			Level 2		Level 3		Total
	Liabilities:
	Fair value of share warrants	$	—		$	—	$	421	$	421
	Total liabilities measured at fair value	$	—		$	—	$	421	$	421
Summary of Change in Estimated Fair Value of Share Warrant Liabilities	'
	The change in the estimated fair value of share warrant liabilities is summarized below:
	March 31,2014	$	421
	Exercise of warrants		—
	Transfer of liability to shareholders' equity upon the conversion of the preference share		(421	)
	warrant to a warrant in respect of ordinary shares
	Issue of ordinary share warrants as part of the company's initial public offering		8,529
	Change in fair value of ordinary share warrants		(984	)
	30-Sep-14	$	7,545

Ordinary_Deferred_and_Preferen1

Ordinary, Deferred and Preference Shares (Tables)	6 Months Ended
	Sep. 30, 2014
Preference Shares [Member]	'
Summary of Shares Issued and Outstanding	'
	The Company’s issued and outstanding preference shares consist of the following:
		Shares Issued				Liquidation
		and Outstanding				amount per share
		Sept 30,		March 31,		Sept 30,		March 31,
		2014		2014		2014		2014
	A Preference shares		—		12,719,954	$	—	$	1.32
	B Preference shares		—		14,583,407	$	—	$	1.28
	C Preference shares		—		929,167	$	—	$	3.11
	Total		—		28,232,528
Ordinary and Deferred Shares [Member]	'
Summary of Shares Issued and Outstanding	'
	The Company’s issued and outstanding ordinary and deferred shares consist of the following:
		Shares Issued
		and Outstanding
		Sept 30,		March 31,		Par value
		2014		2014
	Ordinary shares		14,376,547		60,044	$	—
	A Ordinary shares		—		244,141		—
	B Ordinary shares		—		37,957		—
	Total		14,376,547		342,142	$	—

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Share Option Activity	'
	The following table summarizes share option activity:
			Number			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life (Months)		Aggregate
			of Share Options								Intrinsic
			Outstanding								Value (1)
	Outstanding — March 31, 2014			779,462		$	2.92		109		$	3,960
	Granted			556,500			8.07		120			—
	Exercised			—			—			—		—
	Forfeited			(15,480	)		—			—		—
	Outstanding — September 30, 2014			1,320,482		$	5.06		108		$	5,771
	Exercisable — September 30, 2014			206,112		$	1.94		101		$	1,544
	-1	Intrinsic value is calculated as the difference between the fair value of the Company’s ordinary shares as of the end of each reporting period and the exercise price of the option. The Company’s closing share price on September 30, 2014 was $9.43.
Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value	'
	The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value, if any:
	Grant Date		Number of			Weighted Average Exercise Prices			Ordinary Shares		Intrinsic
			Options Granted						Fair Value Per		Value
									Share at Grant
									Date
	29-Apr-14			524,900		$	8		$	8	$	—
	6-Aug-14			31,600		$	9.26		$	9.26	$	—
Summary of Weighted-Average Assumptions to Share Options Issued	'
	A summary of the weighted-average assumptions applicable to the share options issued in the current financial year is as follows:
			29-Apr-14			6-Aug-14
	Risk-free interest rate			2.69	%		2.46	%
	Weighted average expected lives (years)			3			3
	Volatility			59.83	%		59.39	%
	Dividend yield			—			—
	Weighted average grant date fair value (per share)		$	8		$	9.26
	Number granted			524,900			31,600

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	6 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of Earnings Per Share Basic and Diluted	'
	The following table sets forth the computation of basic and diluted earnings per ordinary share.
		Quarter ended						Six months ended
		30-Sep						30-Sep
		2014			2013			2014			2013
	Numerator:
	Net loss	$	(11,719	)	$	(2,079	)	$	(14,335	)	$	(1,685	)
	Net loss available to ordinary shareholders	$	(11,719	)	$	(2,079	)	$	(14,335	)	$	(1,685	)
	- basic and diluted
	Denominator:
	Weighted-average shares outstanding		14,376,547			288,661			13,584,197			263,088
	- basic and diluted
	Loss per share - basic and diluted	$	(0.82	)	$	(7.20	)	$	(1.06	)	$	(6.41	)

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
Accounting Policies [Abstract]	'	'	'	'
Cash and cash equivalents	$17,110,000	$7,192,000	$1,540,000	$4,219,000
Restricted cash	319,000	345,000	'	'
Anticipated gross expenditure	$30,000,000	'	'	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

In Thousands, unless otherwise specified

Jun. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Customer

Customer

Customer

Customer

CE-Marks [Member]

FDA [Member]

CE-Marks & FDA [Member]

Milestone Payment One [Member]

Customer Relationships [Member]

Brands Associated with Acquired Cell Lines [Member]

Product Licenses [Member]

Other Intangible Assets [Member]

Minimum [Member]

Maximum [Member]

Inventories [Member]

Inventories [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Sales [Member]

Sales [Member]

Payments

Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

'

$319

'

$319

'

$345

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of cash and cash equivalents held by Company and its U.S subsidiary

'

100.00%

'

100.00%

'

99.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of customer represent 10% or more of accounts receivable

'

1

'

1

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

53.00%

37.00%

54.00%

58.00%

Number of customer represent 10% or more of accounts receivable

'

'

'

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation cost

'

283

223

509

422

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

Plant, machinery and equipment useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'25 years

'

'

'

'

'

'

Intangible assets amortization over estimated useful life

'

'

'

'

'

'

'

'

'

'

'5 years

'40 years

'10 years

'7 years

'

'

'

'

'

'

'

'

Impairment losses

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone amount receivable upon fulfillment of target order

'

'

'

'

'

'

2,750

1,400

500

650

'

'

'

'

'

'

'

'

'

'

'

'

Number of milestone payments

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone cumulative orders target

250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Milestone revenue recognized

'

'

'

'

$2,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$4,821	$4,762
Accumulated Amortization	-3,742	-3,795
Net Carrying Amount	1,079	967
Customer Relationships [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	3,192	3,283
Accumulated Amortization	-3,192	-3,283
Brands Associated with Acquired Cell Lines [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	658	677
Accumulated Amortization	-116	-112
Net Carrying Amount	542	565
Weighted-Average Remaining Useful Life	'32 years 10 months 24 days	'33 years 4 months 24 days
Product Licenses [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	763	589
Accumulated Amortization	-226	-200
Net Carrying Amount	537	389
Weighted-Average Remaining Useful Life	'7 years	'6 years 7 months 6 days
Other Intangible Assets [Member]	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	208	213
Accumulated Amortization	-208	-200
Net Carrying Amount	'	$13
Weighted-Average Remaining Useful Life	'	'4 months 24 days

Debt_Schedule_of_LongTerm_Debt

Debt - Schedule of Long-Term Debt (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Total debt	$15,000	$15,000
Less current portion	-1,500	'
Long-term debt	13,500	15,000
Fees due on final repayment of debt	487	487
Fair value of associated share warrant, net of amortization	-295	-382
Long-term debt, less current portion	$13,692	$15,105

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 09, 2013
Debt Instrument [Line Items]	'	'
Margin over LIBOR rate	6.70%	'
Long-term debt repayable terms	'no repayments being due until 18 months from the date of drawdown and then equal amounts being repayable monthly over the remaining 30 months.	'
Facility bears interest	'LIBOR plus 6.7%	'
LIBOR rate applicable terms	'LIBOR rate applicable is the higher of the actual market rate from time to time or 2.0%.	'
MidCap Financial LLC [Member]	'	'
Debt Instrument [Line Items]	'	'
Drew down with new secured bank facility agreement	'	$15,000
Facility repayable period	'4 years	'

Debt_Schedule_of_Outstanding_D

Debt - Schedule of Outstanding Debt (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Long-term Debt, Current Maturities [Abstract]	'	'
Within 1 year	$1,500	'
Between 1 and 2 years	6,000	'
Between 2 and 3 years	6,000	'
Between 3 and 4 years	1,500	'
Total debt	$15,000	$15,000

Consolidated_Balance_Sheet_Det2

Consolidated Balance Sheet Detail - Summary of Inventory (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$1,214	$1,420
Work in progress	2,353	2,031
Finished goods	857	1,106
Total inventories	$4,424	$4,557

Consolidated_Balance_Sheet_Det3

Consolidated Balance Sheet Detail - Summary of Property and Equipment (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Property Plant And Equipment [Abstract]	'	'
Plant and Machinery	$15,109	$7,063
Leasehold improvements	5,199	3,594
Total property and equipment	20,308	10,657
Less: accumulated depreciation	-2,572	-2,101
Total property and equipment, net	$17,736	$8,556

Consolidated_Balance_Sheet_Det4

Consolidated Balance Sheet Detail - Additional Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'	'
Depreciation expenses	$557	$188

Consolidated_Balance_Sheet_Det5

Consolidated Balance Sheet Detail - Summary of Accrued Compensation and Benefits (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Compensation Related Costs [Abstract]	'	'
Salary and related benefits	$151	$75
Accrued vacation	25	26
Accrued payroll taxes	335	281
Accrued incentive payments	1,257	1,632
Total accrued compensation and benefits	$1,768	$2,014

Consolidated_Balance_Sheet_Det6

Consolidated Balance Sheet Detail - Summary of Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued legal and professional fees	$125	$2,007
Accrued interest	109	112
Goods received not invoiced	582	590
Accrued development expenditure	4,178	799
Other accrued expenses	961	945
Total accrued expenses and other current liabilities	$5,955	$4,453

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2008	Sep. 30, 2014	Apr. 30, 2014
	GBP (£)	GBP (£)	USD ($)	USD ($)
			Contracts
Commitments And Contingencies Disclosure [Abstract]	'	'	'	'
Research and development grant funding from Scottish Enterprise	'	£ 1,791	'	'
Claims from grant	1,790	'	'	'
Number of forward exchange contracts	'	'	9	'
Forward exchange contracts sold	'	'	$300,000	'
Forward exchange contracts exchange rate pounds sterling to US dollar	1.7227	'	'	'
Issued warrants to acquire common shares	'	'	'	5,000,000
Ordinary share acquired for each unit of warrant	'	'	'	0.8
Whole share price	'	'	$9.43	$8.80

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Recurring [Member], USD $)	Sep. 30, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Assets:	'	'
Total assets measured at fair value	$0	$94
Liabilities:	'	'
Total liabilities measured at fair value	7,704	421
Level 1 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	94
Liabilities:	'	'
Total liabilities measured at fair value	7,704	'
Level 2 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	'
Level 3 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	'
Liabilities:	'	'
Total liabilities measured at fair value	'	421
Foreign Currency Forward Contracts [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	94
Liabilities:	'	'
Total liabilities measured at fair value	159	'
Foreign Currency Forward Contracts [Member] | Level 1 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	94
Liabilities:	'	'
Total liabilities measured at fair value	159	'
Foreign Currency Forward Contracts [Member] | Level 2 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	'
Foreign Currency Forward Contracts [Member] | Level 3 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	'
Fair Value of Preference Share Warrants [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	7,545	421
Fair Value of Preference Share Warrants [Member] | Level 1 [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	7,545	'
Fair Value of Preference Share Warrants [Member] | Level 3 [Member]	'	'
Liabilities:	'	'
Total liabilities measured at fair value	'	$421

Commitments_and_Contingencies_3

Commitments and Contingencies - Summary of Change in Estimated Fair Value of Share Warrant Liabilities (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Warrant at fair value, Beginning balance	$421
Exercise of warrants	0
Transfer of liability to shareholders' equity upon the conversion of the preference share warrant to a warrant in respect of ordinary shares	-421
Issue of ordinary share warrants as part of the company's initial public offering	8,529
Change in fair value of financial liability in respect of share warrants	-984
Warrant at fair value, Ending balance	$7,545

Ordinary_Deferred_and_Preferen2

Ordinary, Deferred and Preference Shares - Summary of Shares Issued and Outstanding (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Class Of Stock [Line Items]	'	'
Common stock, shares outstanding	14,376,547	342,142
Common stock, shares issued	14,376,547	342,142
Common stock, par value	'	'
Preferred stock, shares outstanding	0	28,232,528
Preferred stock, shares issued	0	28,232,528
A Ordinary Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Common stock, shares outstanding	0	244,141
Common stock, shares issued	0	244,141
Common stock, par value	'	'
B Ordinary Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Common stock, shares outstanding	0	37,957
Common stock, shares issued	0	37,957
Common stock, par value	'	'
A Preference Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Preferred stock, shares outstanding	0	12,719,954
Preferred stock, shares issued	0	12,719,954
Liquidation amount per share	$0	1.32
B Preference Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Preferred stock, shares outstanding	0	14,583,407
Preferred stock, shares issued	0	14,583,407
Liquidation amount per share	$0	1.28
C Preference Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Preferred stock, shares outstanding	0	929,167
Preferred stock, shares issued	0	929,167
Liquidation amount per share	$0	3.11
Ordinary Shares [Member]	'	'
Class Of Stock [Line Items]	'	'
Common stock, shares outstanding	14,376,547	60,044
Common stock, shares issued	14,376,547	60,044
Common stock, par value	'	'

Ordinary_Deferred_and_Preferen3

Ordinary, Deferred and Preference Shares - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Shares conversion description	'On April 3, 2014, all of the outstanding A ordinary shares, B ordinary shares and preference shares were converted into ordinary shares. The ordinary shares then outstanding were consolidated on the basis of 32 new ordinary shares for every existing 100 ordinary shares.
Existing ordinary shares issued 32 new ordinary shares	100
New ordinary shares issued for every existing 100 ordinary shares	32

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Share-based compensation	$283	$223	$509	$422
Risk-free interest rate, Description	'	'	'Risk-Free Interest Rate. The risk-free interest rate is based on the UK Government 10 year bond yield in effect at the time of grant.	'
Restricted Stock Units (RSUs)	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'4 years	'
Number of restricted stock units awarded to non-executive director	50,000	'	'	'
Employee Stock Option [Member] | Minimum [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'1 year	'
Employee Stock Option [Member] | Maximum [Member]	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Vesting period	'	'	'3 years	'

ShareBased_Compensation_Summar

Share-Based Compensation - Summary of Share Option Activity (Detail) (USD $)	0 Months Ended		6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 06, 2014	Apr. 29, 2014	Sep. 30, 2014	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'
Number of Share Options Outstanding, Beginning Balance	'	'	779,462	'
Number of Share Options Outstanding, Granted	31,600	524,900	556,500	'
Number of Share Options Outstanding, Exercised	'	'	0	'
Number of Share Options Outstanding, Forfeited	'	'	-15,480	'
Number of Share Options Outstanding, Ending Balance	'	'	1,320,482	779,462
Number of Share Options Outstanding, Exercisable	'	'	206,112	'
Weighted-Average Exercise Price, Beginning Balance	'	'	$2.92	'
Weighted-Average Exercise Price, Granted	'	'	$8.07	'
Weighted-Average Exercise Price, Exercised	'	'	$0	'
Weighted-Average Exercise Price, Forfeited	'	'	$0	'
Weighted-Average Exercise Price, Ending Balance	'	'	$5.06	$2.92
Weighted-Average Exercise Price, Exercisable	'	'	$1.94	'
Weighted-Average Remaining Contractual Life, outstanding	'	'	'108 months	'109 months
Weighted-Average Remaining Contractual Life, Granted	'	'	'120 months	'
Weighted-Average Remaining Contractual Life, Exercisable	'	'	'101 months	'
Aggregate Intrinsic Value, Beginning Balance	'	'	$3,960	'
Aggregate Intrinsic Value, Ending Balance	'	'	5,771	3,960
Aggregate Intrinsic Value, Exercisable	'	'	$1,544	'

ShareBased_Compensation_Summar1

Share-Based Compensation - Summary of Share Option Activity (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Apr. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Company's closing share price	$9.43	$8.80

ShareBased_Compensation_Summar2

Share-Based Compensation - Summary of Share Option Granted, Exercise Price, Fair Value, Intrinsic Value (Detail) (USD $)	0 Months Ended		6 Months Ended
	Aug. 06, 2014	Apr. 29, 2014	Sep. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Number of Options Granted	31,600	524,900	556,500
Weighted Average Exercise Prices	'	'	$8.07
Ordinary Shares Fair Value Per Share at Grant Date	$9.26	$8	'
29-Apr-14	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Grant Date	'	'	29-Apr-14
Number of Options Granted	'	'	524,900
Weighted Average Exercise Prices	'	'	$8
Ordinary Shares Fair Value Per Share at Grant Date	'	'	$8
Intrinsic Value	'	'	$0
6-Aug-14	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'
Grant Date	'	'	6-Aug-14
Number of Options Granted	'	'	31,600
Weighted Average Exercise Prices	'	'	$9.26
Ordinary Shares Fair Value Per Share at Grant Date	'	'	$9.26
Intrinsic Value	'	'	$0

ShareBased_Compensation_Summar3

Share-Based Compensation - Summary of Weighted-Average Assumptions to Share Options Issued (Detail) (USD $)	0 Months Ended		6 Months Ended
	Aug. 06, 2014	Apr. 29, 2014	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Risk-free interest rate	2.46%	2.69%	'
Weighted average expected lives (years)	'3 years	'3 years	'
Volatility	59.39%	59.83%	'
Dividend yield	0.00%	0.00%	'
Weighted average grant date fair value (per share)	$9.26	$8	'
Number of Share Options Outstanding, Granted	31,600	524,900	556,500

Net_Loss_Per_Share_Computation

Net Loss Per Share - Computation of Earnings Per Share Basic and Diluted (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net loss	($11,719)	($2,079)	($14,335)	($1,685)
Net loss available to ordinary shareholders - basic and diluted	($11,719)	($2,079)	($14,335)	($1,685)
Denominator:	'	'	'	'
Weighted-average shares outstanding - basic and diluted	14,376,547	288,661	13,584,197	263,088
Loss per share - basic and diluted	($0.82)	($7.20)	($1.06)	($6.41)

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail) (A Preference Shares [Member], USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
A Preference Shares [Member]	'
Earnings Per Share, Basic, Two Class Method [Abstract]	'
Cumulative dividend included in net loss for EPS calculation	$0